ASCO GU 2018 Renal Cancer - Results from #40

Viewing 41-60 of 68 articles

ASCO GU 2018: Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: Past, Present, and Future

ASCO GU 2018: Phase III Trial of Adjuvant Sunitinib in Patients with High-risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

ASCO GU 2018: Safety and Efficacy of Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer

ASCO GU 2018: Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

ASCO GU 2018: A Randomized Phase II Trial of Pazopanib versus Temsirolimus in Patients with Advanced Clear-cell Renal Cell Carcinoma (the TemPa trial)

ASCO GU 2018: Homologous Repair Deficiency in VHL-mutated Clear Cell Renal Cell Carcinoma

ASCO GU 2018: IMmotion 151: A randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma

ASCO GU 2018: Germline Pathogenic Variants in Patients with Pheochromocytoma

ASCO GU 2018: Impact of Tumor Size on Survival Outcome in mRCC Treated with Targeted Therapy

ASCO GU 2018: Phase III, Randomized, Double-blind Trial of Pembrolizumab in the Adjuvant Treatment of RCC: KEYNOTE-564

ASCO GU 2018: Effect of Crizotinib on Disease Control in Patients with Advanced Papillary Renal Cell Carcinoma - Final Results of EORTC 90101 CREATE

ASCO GU 2018: Best of Journals: Renal Cell Carcinoma - Radiology

ASCO GU 2018: The Probability of Indolent Versus Aggressive Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment

ASCO GU 2018: Survival Following Upfront Cytoreductive Nephrectomy Versus Targeted Therapy for Metastatic Renal Cell Carcinoma

ASCO GU 2018: Timing and Patient Selection for Cytoreductive Nephrectomy

ASCO GU 2018: Value of the Lymph Node Dissection in the M0 and M1 Patient

ASCO GU 2018: Phase Ib Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma or Renal Cell Carcinoma

ASCO GU 2018: Safety and Efficacy of Nivolumab in Metastatic Renal Cell Carcinoma: Results From the NIVOREN GETUG-AFU 26 Study

ASCO GU 2018: Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial - Advanced Renal Cell Carcinoma

ASCO GU 2018: Best of Journals: Kidney Cancer - Urology

1
2
3
4